Slide 1: One Company. Endless Possibilities
One Company. Endless Possibilities CONFERENCE CALL First nine months 2024 results November 8, 2024
Slide 2: Presenting team
Presenting team Valerie Diele-Braun Hans Kooijmans CEO CFO 2
Slide 3: Agenda
1 Company profile 2 Highlights first nine months 2024 3 Financials first nine months 2024 4 Outlook 5 Q&A 3
Slide 4: Profile
Profile IMCD is a market leader in the sales, marketing and distribution of speciality chemicals and ingredients Highlights: ● Formulatory and solutions provider ● Comprehensive and complementary product portfolio ● Multi-territory distribution management in EMEA, Asia-Pacific and Americas ● Headqua
Slide 5: Highlights first nine months 2024
Company Highlights first Financials first Outlook Q&A profile nine months nine months 2024 2024 5
Slide 6: Highlights first nine months 2024
Highlights first nine months 2024 Gross profit • Gross profit increase of 6% to EUR 909 million (+8% on a constant currency basis) Operating EBITA • Operating EBITA increase of 1% to EUR 403 million (+3% on a constant currency basis) Free cash flow • Free cash flow of EUR 299 million (first nine mon
Slide 7: Highlights – acquisitions since June 2024
Highlights first nine months 2024 – acquisitions since June 2024 EMEA • On 1 July 2024, IMCD acquired 100% of the shares of Arena Pharmaceuticals Ltd. and Pethel Marali Ltd. (together: “Arena”), an UK distributor of API’s. • On 17 July 2024, IMCD acquired 100% of the shares of in Cobapharma, a Europ
Slide 8: Financials first nine months 2024
Highlights first Financials first Outlook Q&A Company nine months profile nine months 2024 2024 8
Slide 9: Financials: Key figures
Financials first nine months 2024 Key figures Jan.1 - Sept. 30 Jan.1 - Sept. 30 Change Change % Fx adj. Change 2024 2023 EUR million Revenue 3,584 3,379 205 6% 7% Gross profit 909 856 53 6% 8% Gross profit as a % of revenue 25.4% 25.3% 0.1% Operating EBITA 403 400 3 1% 3% Operating EBITA as a % of r
Slide 10: Financials: Income statement
Financials first nine months 2024 Income statement Asia Holding EUR million EMEA Americas Pacific companies Total Gross profit YTD Q3 2024 422 273 214 909 YTD Q3 2023 406 261 189 856 organic growth 2% -% 1% -% acquisition growth 3% 6% 14% 7% currency impact (1%) (1%) (2%) (1%) Operating EBITA YTD Q3
Slide 11: Financials: Free cash flow
Financials first nine months 2024 Free cash flow Jan.1 - Sept. 30 Jan.1 - Sept. 30 Change Change % 2024 2023 EUR million Operating EBITA 403 400 3 1% Depreciation 31 24 7 Operating EBITDA 434 424 10 2% Share based payments 3 4 (1) IAS 17 lease payments (24) (19) (5) Adjusted operating EBITDA 413 408
Slide 12: Financials: Net debt/leverage
Financials first nine months 2024 Net debt/leverage 30 September 31 December 30 September 2024 2023 2023 EUR million Reported Net Debt 1,585 1,286 1,352 Reported leverage ratio: Reported (incl. full year impact of acquisitions) 2.8 2.3 2.4 Leverage ratio based on loan documentation: Actual based on
Slide 13: Outlook
Highlights first Financials first Outlook Q&A Company nine months nine months profile 2024 2024 13
Slide 14: Outlook
Outlook IMCD operates in different, often fragmented market segments in multiple geographic regions, connecting many customers and suppliers across a very diverse product range. In general, results are impacted by macroeconomic conditions and developments in specific industries. Results can be influ
Slide 15: Q&A
Highlights first Financials first Outlook Q&A Company nine months nine months profile 2024 2024 15
Slide 16: Disclaimer
Disclaimer This presentation may contain forward looking statements. These statements are based on current expectations, estimates and projections of IMCD’s management and information currently available to the company. IMCD cautions that such statements contain elements of risk and uncertainties th
Slide 17: One company. Endless possibilities
Find us on: One company. Endless possibilities